Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Duffel – page 140

1 991 clinical trials in Duffel, Belgium across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Duffel at a glance
1 991
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 991 trials in Duffel

Open in trial search

Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Study on Tezepelumab for Symptom Relief in Patients Aged 12-80 with Eosinophilic Esophagitis

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Study of Eftilagimod Alpha and Paclitaxel in Patients with HER2-Negative/Low Metastatic Breast Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Eftilagimod Alfa
  • Sponsor:Immutep

Study of datopotamab deruxtecan combined with immunotherapy and carboplatin in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:ITM Solucin GmbH

Study on Livmoniplimab and Budigalimab with Chemotherapy for Adults with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Long-Term Safety of Bepranemab for Adults with Progressive Supranuclear Palsy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bepranemab
  • Sponsor:UCB Biopharma

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Study Comparing Sacituzumab Govitecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Gilead Sciences Inc.

Study on R3R01 for Patients with Alport Syndrome and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:R3R01
  • Sponsor:River 3 Renal Corp.

Colitis ulcerative

Not recruiting

Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Tofacitinib
  • Sponsor:Pfizer Inc.

Study of Cemiplimab Compared to Placebo After Surgery and Radiation for Patients with High-Risk Skin Squamous Cell Carcinoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Duffel

What the registry says about research in the country

01 Mental Health Research

Groundbreaking research focusing on Major Depressive Disorder and treatment-resistant depression, exploring novel therapeutic approaches and augmentation strategies.

  • Antidepressant Augmentation Studies
  • Treatment Response Assessment
  • Dose Optimization Research

Current trials are evaluating innovative treatment combinations and dosing strategies for patients who haven't achieved optimal results with standard therapies.

02 Psychiatric Disorders

Comprehensive research into schizophrenia, particularly focusing on cognitive impairment and long-term treatment outcomes with novel therapeutic agents.

  • Cognitive Function Studies
  • Long-term Safety Assessments
  • Treatment Effectiveness Monitoring

These studies aim to enhance our understanding of long-term treatment safety and efficacy in schizophrenia management.

03 Innovative Therapies

Exploring immune-targeted treatments and novel pharmaceutical approaches for treatment-resistant depression, including anti-inflammatory strategies.

  • Inflammation-based Treatments
  • Alternative Therapeutic Approaches
  • Biomarker Studies

Research focuses on identifying and validating new treatment pathways for patients who haven't responded to conventional therapies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.